Pénault-Llorca F - Search Results

1

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group. Coudert B, et al. Oncologist. 2012;17(7):900-9. doi: 10.1634/theoncologist.2011-0442. Epub 2012 May 18. Oncologist. 2012. PMID: 22610153 Free PMC article. Clinical Trial.

2

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault-Llorca F, Buyse M, Pouillart P. Diéras V, et al. J Clin Oncol. 2004 Dec 15;22(24):4958-65. doi: 10.1200/JCO.2004.02.122. J Clin Oncol. 2004. PMID: 15611510 Clinical Trial.

3

Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.

Abrial C, Van Praagh I, Delva R, Leduc B, Fleury J, Gamelin E, Sillet-Bach I, Penault-Llorca F, Amat S, Chollet P. Abrial C, et al. Oncologist. 2005 Apr;10(4):242-9. doi: 10.1634/theoncologist.10-4-242. Oncologist. 2005. PMID: 15821244 Free article. Clinical Trial.

4

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Arnould L, et al. Br J Cancer. 2006 Jan 30;94(2):259-67. doi: 10.1038/sj.bjc.6602930. Br J Cancer. 2006. PMID: 16404427 Free PMC article. Clinical Trial.

5

Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.

Amat S, Mouret-Reynier MA, Penault-Llorca F, Leheurteur M, Delva R, Coudert B, Leduc B, Dauplat J, Curé H, Chollet P. Amat S, et al. Clin Breast Cancer. 2006 Aug;7(3):262-9. doi: 10.3816/CBC.2006.n.039. Clin Breast Cancer. 2006. PMID: 16942644 Clinical Trial.

6

Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.

Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Leheurteur M, Gimbergues P, Tortochaux J, Curé H, Chollet P. Penault-Llorca F, et al. Oncologist. 2007 Apr;12(4):390-6. doi: 10.1634/theoncologist.12-4-390. Oncologist. 2007. PMID: 17470681 Free article.

7

Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy.

Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Curé H, Chollet P. Tacca O, et al. Oncologist. 2007 Jun;12(6):636-43. doi: 10.1634/theoncologist.12-6-636. Oncologist. 2007. PMID: 17602055 Free article.

8

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.

Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, Sagan C, Antoine M, Penault-Llorca F, Vasseur B, Fumoleau P, Coudert BP. Arnould L, et al. Clin Cancer Res. 2007 Nov 1;13(21):6404-9. doi: 10.1158/1078-0432.CCR-06-3022. Clin Cancer Res. 2007. PMID: 17975153

9

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.

Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Dômont J, Spielmann M, Delaloge S, André F, Penault-Llorca F. Bidard FC, et al. Ann Oncol. 2008 Jul;19(7):1261-1265. doi: 10.1093/annonc/mdn039. Epub 2008 Mar 5. Ann Oncol. 2008. PMID: 18325917 Free article.

10

Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Andre F, et al. J Clin Oncol. 2008 Jun 1;26(16):2636-43. doi: 10.1200/JCO.2007.14.9146. J Clin Oncol. 2008. PMID: 18509176

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

502 results

Search Page

Filters